Results 21 to 30 of about 1,140,223 (331)

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

New England Journal of Medicine, 2021
BACKGROUND Patients with renal-cell carcinoma who undergo nephrectomy have no options for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting evidence. METHODS In a double-blind, phase 3 trial, we randomly assigned, in
T. Choueiri, P. Tomczak, S. Park, B. Venugopal, T. Ferguson, Yen‐Hwa Chang, J. Hajek, S. Symeonides, Jae Lyun Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, N. Haas, P. Sawrycki, H. Gurney, C. Chevreau, B. Melichar, Evgeniy Kopyltsov, A. Alva, J. Burke, G. Doshi, D. Topart, S. Oudard, H. Hammers, H. Kitamura, J. Bedke, R. Perini, Pingye Zhang, K. Imai, Jaqueline Willemann-Rogerio, D. Quinn, T. Powles   +32 more
semanticscholar   +1 more source

Renal cell carcinoma

BMJ, 2014
The treatment of renal cell carcinoma (RCC) has changed greatly over the past 15 years. Progress in the surgical management of the primary tumor and increased understanding of the molecular biology and genomics of the disease have led to the development of new therapeutic agents.
W. Kimryn Rathmell, Jianjun Gao, Eric Jonasch   +2 more
openaire   +3 more sources

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

New England Journal of Medicine, 2007
BACKGROUND Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted.
R. Motzer, Thomas E. Hutson, P. Tomczak, M. Michaelson, R. Bukowski, O. Rixe, S. Oudard, S. Négrier, C. Szczylik, Sindy T. Kim, I. Chen, P. Bycott, C. Baum, R. Figlin   +13 more
semanticscholar   +1 more source

Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.

New England Journal of Medicine, 2021
BACKGROUND Patients with von Hippel-Lindau (VHL) disease have a high incidence of renal cell carcinoma owing to VHL gene inactivation and constitutive activation of the transcription factor hypoxia-inducible factor 2α (HIF-2α). METHODS In this phase 2,
E. Jonasch, F. Donskov, O. Iliopoulos, W. Rathmell, V. Narayan, B. Maughan, S. Oudard, T. Else, J. Maranchie, S. Welsh, S. Thamake, E. Park, R. Perini, W. Linehan, R. Srinivasan   +14 more
semanticscholar   +1 more source

Hereditary papillary renal cell carcinoma primarily diagnosed in a cervical lymph node: a case report of a 30-year-old woman with multiple metastases

BMC Urology, 2013
Background Papillary renal cell carcinoma is a rare cancer. Some cases can be attributed to individuals with hereditary renal cell carcinomas usually consisting of the clear cell subtype.
Behnes Carl Ludwig, Schlegel Christina, Shoukier Moneef, Magiera Isabella, Henschke Frank, Schwarz Alexander, Bremmer Felix, Loertzer Hagen   +7 more
doaj   +1 more source

Renal cell carcinoma [PDF]

World Journal of Urology, 2016
Renal cell cancer (RCC) accounts for approximately 2–3 % of all human malignancies and shows a worldwide increase of incidence rate of 2 % per year [1]. It primarily affects men and women at the age of 50–70 years with a twofold higher incidence rate in men.
Börje Ljungberg, Axel Bex, Axel S. Merseburger   +2 more
openaire   +3 more sources

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline

Journal of Clinical Oncology, 2022
PURPOSE To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations. RESULTS The
W. Rathmell, R. Rumble, P. V. Van Veldhuizen, H. Al-Ahmadie, H. Emamekhoo, R. Hauke, A. Louie, M. Milowsky, A. Molina, T. Rose, S. Siva, Nicholas G Zaorsky, Tian Zhang, R. Qamar, Terry M Kungel, Bryan Lewis, E. Singer   +16 more
semanticscholar   +1 more source

The Labyrinth of Renal Cell Carcinoma [PDF]

Cancers, 2020
Renal cell carcinoma (RCC) ranks in the top-ten list of malignancies both in males and females [...]
Claudia Manini, José I. López
openaire   +4 more sources

Sorafenib in advanced clear-cell renal-cell carcinoma.

New England Journal of Medicine, 2007
BACKGROUND We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.
B. Escudier, T. Eisen, W. Stadler, C. Szczylik, S. Oudard, M. Siebels, S. Négrier, C. Chevreau, E. Solska, A. Desai, F. Rolland, T. Demkow, Thomas E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, R. Bukowski   +18 more
semanticscholar   +1 more source

Epidemiology of Renal Cell Carcinoma

World Journal of Oncology, 2020
Though renal cell carcinoma (RCC) accounts for 2% of global cancer diagnoses and deaths, it has more than doubled in incidence in the developed world over the past half-century, and today is the ninth most common neoplasm in the United States (US). While
S. Padala, A. Barsouk, K. Thandra, Kalyan Saginala, A. Mohammed, Anusha Vakiti, Prashanth Rawla, Alexander Barsouk   +7 more
semanticscholar   +1 more source